Fulltext

Corrigendum to "A narrative review of approved and emerging anti-obesity medications" [Saudi Pharm. J. 31(10) (2023) 101757]

Beshir SA 1 , Elnour AA 2 , Soorya A 3 , Mohamed AP 4 , Goh SSL 5 , Hussain N 6 Show all authors , Al Haddad AHI 7 , Hussain F 8 , El Khidir IY 9 , Abdelnassir Z 10

Affiliations 

  • 1 Department of clinical pharmacy and Pharmacotherapeutics, Dubai Pharmacy College For Girls, Dubai, United Arab Emirates
  • 2 Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Abu Dhabi Campus, United Arab Emirates
  • 3 College of Medicine, Gulf Medical University, Ajman, United Arab Emirates
  • 4 College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates
  • 5 Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 6 Department of Pharmaceutical Sciences, College of Pharmacy, 105949, Al Ain University, Al Ain, United Arab Emirates
  • 7 Chief Operation Officer, Sheikh Shakhbout Medical City (SSMC), Abu Dhabi, United Arab Emirates
  • 8 Department of clinical pharmacy and Therapeutics, Dubai Pharmacy College, Dubai, United Arab Emirates
  • 9 Department of Clinical Pharmacy and Pharmacy Practice, (PhD, MSc, B Pharm), College of Pharmacy, Najran University, Najran -King Saudi Arabia (KSA), Saudi Arabia
  • 10 Fourth-year pharmacy, Abu Dhabi, United Arab Emirates
Saudi Pharm J, 2024 May;32(5):102047.
PMID: 38596318 DOI: 10.1016/j.jsps.2024.102047

Abstract

[This corrects the article DOI: 10.1016/j.jsps.2023.101757.].

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications